NCT02877355View on ClinicalTrials.gov

Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

August 22, 2016

Primary Completion Date

November 24, 2017

Study Completion Date

November 24, 2017

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

semaglutide

All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days

Trial Locations (2)

41460

Novo Nordisk Investigational Site, Neuss

55116

Novo Nordisk Investigational Site, Mainz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY